ArticleFrontiers in microbiology2025
Constructing inflammatory bowel disease diagnostic models based on k-mer and machine learning.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Worldwide research trends on theFrontiers in immunology · 2026Pooled it
- Recent Advances in Artificial Intelligence for Endoscopic and Multimodal Assessment of Inflammatory Bowel Disease: A Review.International journal of general medicine · 2026Review
- Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting.Journal of innate immunity · 2026Review
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Artificial intelligence empowers gut microbiota research in neurodegenerative diseases molecular mechanisms and precision therapy.iScience · 2025Review
- Utility of Machine Learning to Characterize Gut Microbiota Dysbiosis and Its Clinical Implications in Inflammatory Bowel Disease.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is linked to significant alterations in gut microbiota. Conventional diagnostic approaches frequently rely on invasive procedures, contributing to patient discomfort; hence, non-invasive diagnostic models present a valuable clinical alternative. Methods: Metagenomic and amplicon sequencing data were collected from fecal samples of patients with IBD and healthy individuals across diverse geographic regions. Diagnostic models were developed using Logistic Regression (LR), Support Vector Machine (SVM), Naïve Bayes (NB), and Feedforward Neural Network (FFNN), complemented by an ensemble model Results: K-mer-based methods leveraging metagenomic sequencing data demonstrated robust diagnostic performance, yielding ROC AUCs of 0.966 for IBD vs. NC and 0.955 for CD vs. UC. Similarly, models based on amplicon sequencing achieved ROC AUCs of 0.831 for IBD vs. NC and 0.903 for CD vs. UC. In comparison, k-mer-based approaches outperformed traditional microbiota-based models, which produced lower ROC AUCs of 0.868 for IBD vs. NC and 0.810 for CD vs. UC. Across all machine learning frameworks, the FFNN consistently attained the highest ROC AUC, underscoring its superior diagnostic performance. Conclusion: The integration of k-mer-based feature extraction with machine learning offers a non-invasive, highly accurate approach for IBD diagnosis, surpassing traditional microbiota-based models. This method holds considerable potential for clinical use, offering an effective alternative to invasive diagnostics and enhancing patient comfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.